

Edgar Filing: IMARX THERAPEUTICS INC - Form SC 13G

IMARX THERAPEUTICS INC
Form SC 13G
February 14, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G

INFORMATION STATEMENT PURSUANT TO RULES 13D-1 AND 13D-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934

(AMENDMENT NO.) (1)

ImaRx Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value per share

(Title or Class of Securities)

45248L100

(CUSIP Number)

December 31, 2007

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

(1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP NO. 45248L100

13G

PAGE 2 OF 6

Edgar Filing: IMARX THERAPEUTICS INC - Form SC 13G

=====

1 NAMES OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

Boston Scientific Corporation

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

N/A (a)
(b)

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

The State of Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5	SOLE VOTING POWER
		1,176,471
	6	SHARED VOTING POWER
		0
	7	SOLE DISPOSITIVE POWER
		1,176,471
	8	SHARED DISPOSITIVE POWER
		0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,176,471

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)

N/A

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11.7%(2)

12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

CO

=====

(2) Based on the number of shares outstanding on November 5, 2007 as set forth in the Quarterly Report on Form 10-Q for the period ended September 30, 2007.

=====

CUSIP NO. 45248L100

=====

13G

=====

PAGE 3 OF 6

=====

ITEM 1(A). NAME OF ISSUER:

ImaRx Therapeutics, Inc., a Delaware corporation (the "Company")

Edgar Filing: IMARX THERAPEUTICS INC - Form SC 13G

ITEM 1(B). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

1635 East 18th Street
Tucson, AZ 85719

ITEM 2(A). NAME OF PERSON FILING:

Boston Scientific Corporation

ITEM 2(B). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

One Boston Scientific Place
Natick, MA 01760-1537

ITEM 2(C). CITIZENSHIP:

The State of Delaware

ITEM 2(D). TITLE OF CLASS OF SECURITIES:

Common Stock, \$0.0001 par value per share, (the "shares")

ITEM 2(E). CUSIP NUMBER:

45248L100

=====
CUSIP NO. 45248L100
=====

13G

=====
PAGE 4 OF 6
=====

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13D-1(B), OR 13D-2(B), CHECK WHETHER THE PERSON FILING IS A:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
- (e) An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with ss. 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

Edgar Filing: IMARX THERAPEUTICS INC - Form SC 13G

=====
CUSIP NO. 45248L100
=====

13G

=====
PAGE 6 OF 6
=====

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2008

(Date)

BOSTON SCIENTIFIC CORPORATION

By: /s/ Lawrence J. Knopf

Name: Lawrence J. Knopf
Title: Senior Vice-President and
Deputy General Counsel

DTH: 100%; TEXT-ALIGN: center">

EXPLANATORY NOTE

The Registrant is filing this Amendment No. 1 to the Form 6-K originally furnished to the Commission on September 10, 2009 to correct a missing conformed signature and date on such Form 6-K.

Other than as expressly set forth above, this Amendment does not, and does not purport to, update or restate any information contained in such Form 6-K.

EXHIBIT LIST

Exhibit	Description
99.1	Trust indenture dated as of August 26, 2009 among the Baytex Energy Trust, Valiant Trust Company and Baytex Energy Ltd., Baytex Oil & Gas Ltd., Baytex Energy Partnership, Baytex

Edgar Filing: IMARX THERAPEUTICS INC - Form SC 13G

Marketing Ltd. and Baytex Energy USA Ltd., as furnished to the Commission on Form 6-K on September 10, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BAYTEX ENERGY TRUST
(Registrant)

By: Baytex Energy Ltd.

Date: September 17, 2009

By: /s/ W. Derek Aylesworth
Name: W. Derek Aylesworth
Title: Chief Financial Officer